Evidence map›Paper›PMID 34208607›Full record

ArticleInternational journal of environmental research and public health2021

Serology in COVID-19: Comparison of Two Methods.

Anna Moniuszko-Malinowska, Wojciech Jelski, Justyna Dunaj, Barbara Mroczko, Piotr Czupryna, Ewelina Kruszewska, Sławomir Pancewicz

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development of practical techniques for simultaneous detection and distinction of current and emerging SARS-CoV-2 variants.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna Moniuszko-MalinowskaDepartment of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland.ORCID 0000-0002-3994-8785
Wojciech JelskiDepartment of Biochemical Diagnostics, Medical University in Bialystok, Jerzego Waszyngtona 15A, 15-269 Białystok, Poland.ORCID 0000-0002-1648-907X
Justyna DunajDepartment of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland.
Barbara MroczkoDepartment of Biochemical Diagnostics, Medical University in Bialystok, Jerzego Waszyngtona 15A, 15-269 Białystok, Poland.ORCID 0000-0002-4075-8479
Piotr CzuprynaDepartment of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland.
Ewelina KruszewskaDepartment of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland.ORCID 0000-0002-6015-2351
Sławomir PancewiczDepartment of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland.

Funding

Uniwersytet Medyczny w Białymstoku 2020
6 · The paper itself

Abstract

backgroundThe aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies.

methodsA total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) and LIAISON

resultsThe assays exhibited a 96.85% (123/127 patients) test result agreement. In two cases, the positive results obtained by SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) were negative based on the LIAISON

conclusionsBased on the results of our study, we conclude that in population medicine, the assessments of anti-SARS-CoV-2 antibodies after exposure to SARS-CoV-2 virus based on spike protein or nucleocapsid protein show comparable effectiveness.

Indexed as

COVID-19Antibodies, ViralHumansImmunoassaySARS-CoV-2Sensitivity and SpecificityAntibodies, Viralchemiluminescent immunoassaynucleocapsid proteinSARS-CoV-2serologyspike protein

Identifiers

PMID34208607
PMCPMC8296394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.